Mahima Datla is among a handful of women leaders in the Indian pharmaceutical sector. Going up against some of the largest vaccine makers in India, her company, Biological E, offered a worthy alternative during the Covid-19 pandemic, and cotinues to export vaccines to over 100 countries
Mahima Datla, Managing director, Biological E
Image: Vikas Chandra Pureti for Forbes India
Mahima Datla likes to think of herself as a “glass half full kind of person”.
Calm, composed and looking for the positives in a situation, the last few years have been nothing, but life-altering for the 46 year- old. It all began sometime in 2020 for the soft-spoken and reticent head of Biological E, a 70-year-old pharmaceutical behemoth, when her company was suddenly propped up into the forefront in India’s defence against Covid-19. Going up against some of the largest vaccine makers in the country, Biological E offered a worthy alternative and helped build India’s Covid-19 war chest.
(This story appears in the 26 January, 2024 issue of Forbes India. To visit our Archives, click here.)